January 31, 2015 11:27 PM ET


Company Overview of DFB Pharmaceuticals, Inc.

Company Overview

DFB Pharmaceuticals, Inc., through its subsidiaries, develops, licenses, and acquires pharmaceutical and medical products that prevent or treat disorders associated with skin and soft tissue. It offers tissue management products to prepare, heal, or treat chronic wounds, such as skin protection products, enzymatic debridement products, wound infection products, and accelerated wound products, as well as biologic and cellular therapies to promote the healing of acute, traumatic, and chronic wounds. The company also provides skin asepsis products, including brush-free surgical scrubs, patient preoperative skin preparations products, and healthcare personnel hand washes. In addition, it offers ...

3909 Hulen Street

Fort Worth, TX 76107

United States

Founded in 1997





Key Executives for DFB Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 78
Chief Financial Officer
Senior Vice President
President of Coria - DFB Branded Pharmaceuticals
Senior Vice President of Research and Development - Branded Pharmaceuticals
Compensation as of Fiscal Year 2014.

DFB Pharmaceuticals, Inc. Key Developments

Attorney General Cuccinelli Announces Settlement with Healthpoint, Ltd. and DFB Pharmaceuticals, Inc. for Illegal Marketing of Xenaderm

Attorney General Ken Cuccinelli announced that it has reached a settlement Healthpoint, Ltd. and its general partner, DFB Pharmaceuticals, for the illegal marketing of Xenaderm, a topical treatment for skin ulcers. The attorney general said that the agreement will resolve allegations that Healthpoint submitted false claims to Virginia's Medicaid program for the unapproved drug. The settlement resolves federal and state False Claims Act cases brought against Healthpoint in the U.S. Federal District Court in Massachusetts. The cases were brought by the U.S. Department of Justice and fifteen plaintiff states. As part of a $48 million settlement announced by the Department of Justice on December 6, 2012, Healthpoint and DFB will pay approximately $33 million total to settle Medicaid-based claims nationally. The settlement will return $223,283.17 to the commonwealth's Medicaid program. The federal and state complaints alleged Healthpoint marketed Xenaderm without FDA approval by modeling it on a pre-1962 drug that the FDA had never reviewed. Additionally, Healthpoint marketed the drug in spite of the FDA's determination in the 1970s that Xenaderm's principal ingredient was less-than-effective for its intended use.

Similar Private Companies By Industry

Company Name Region
Chakshu Research, Inc. United States
Ansun Biopharma, Inc. United States
EnergyAloe, Inc. United States
TobahMaoz, Inc. United States
ARTA Bioscience, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DFB Pharmaceuticals, Inc., please visit www.dfb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.